

Overview of Coil Trials and Registries

Society of Vascular and Interventional Neurology
7th Annual Meeting
November 9, 2014
Hollywood, FL

Marc A. Lazzaro, MD

Assistant Professor of Neurology and Neurosurgery
Vascular Neurology and Neurointervention
Froedtert and Medical College of Wisconsin

Disclosures

- No financial interest in any product or manufacturer mentioned herein.



Talk aims

- ★ Review coiling trials and provide updates



HEAT Trial - Hydrogel vs Bare Platinum

HEAT -Hydrogel Endovascular Aneurysm Treatment trial

National PI	<i>Bernard Bendok, MD</i>
Design	<i>Prospective, randomized, post-market clinical trial</i>
Aim	<i>Compare 2nd generation hydrogel coil technology to bare platinum. Hydroframe/Hydrocoil/Hydrofill/Hydrosoft</i>
Subjects	<i>Ruptured and unruptured; 3-14 mm</i>
Primary outcome	<i>Aneurysm recurrence at any time during follow up (24 months)</i>

Updates:

- 425 patients enrolled to date (target 600)***
-

Gel-the-Nec Registry - Hydrosoft as finishing coil

Gel-the-Nec - Gaining Efficacy Long Term: Hydrosoft, an Emerging, New Embolic Coil

National PI	David Kallmes, MD
Design	Post-market, Multi-center prospective registry to deploy Hydrosoft coils as a finishing coil
Aim	Gain robust clinical data in a large set of patients to better understand the advantages and disadvantages of hydrosoft coils
Subjects	600 subjects, ruptured & unruptured aneurysms 3 - 15 mm
Primary outcome	Safety and efficacy

Updates:

- **Enrollment complete**
 - **600 patients enrolled**
 - **Follow-up is underway**
 - **Periprocedural outcomes will be submitted for publication soon**
-

PRET Trial - Hydrogel vs platinum in aneurysms prone to recurrence

PRET - Patients prone to recurrence after endovascular treatment

National PI	Daniel Roy MD, Jean Raymond MD
Design	Multi-center, prospective, randomized trial of management of aneurysms prone to recurrence comparing hydrogel and platinum coils
Aim	Compare hydrogel coils to bare platinum coils
Subjects	447 (250 large aneurysms (>10mm), 197 recurrent)
Primary outcome	Recurrence rate of target aneurysm

Updates:

- **Completed**
 - **Peri-procedural results AJNR 2014; 35(9): 1667-76.**
 1. **No difference between groups for indices to assess safety up to 30 days.**
 2. **Operator-assessed angiographic outcomes were satisfactory (complete occlusion or residual neck) in 339/444 (76.4%) of patients with no significant difference between groups.**
 - **Follow up data coming**
-

FAR Registry - safety, occlusion feasibility, and stability of hydrosoft coil

FAR - French Aneurysm Registry

<i>National PI</i>	<i>Alain Bonafe, MD</i>
<i>Design</i>	<i>Multi-center registry</i>
<i>Aim</i>	<i>Evaluate safety profile and aneurysm occlusion feasibility and stability associated with the hydrosoft coil</i>
<i>Subjects</i>	<i>102 aneurysms</i>
<i>Primary outcome</i>	<i>Recanalization at 6 months</i>

Updates:

- Completed***
 - Publication pending***
-

GREAT - German trial comparing hydrosoft vs platinum coils

GREAT - German Randomized Endovascular Aneurysm Trial

<i>National PI</i>	<i>Christian Taschner, MD</i>
<i>Design</i>	<i>Multi-center randomized controlled trial</i>
<i>Aim</i>	<i>Evaluate the safety, efficacy, and long-term outcomes of the hydrosoft coil</i>
<i>Subjects</i>	<i>503 patients, aneurysms 4-12 mm</i>
<i>Primary outcome</i>	<i>Recanalization at 6 and 18 month follow up</i>

Updates:

- Completed***
- Publication expected late 2014***

GELATIN Registry

GELATIN -Hydrogel balloon assisted intracranial aneurysm coiling registry

<i>National PI</i>	<i>Sam Zaidat, MD</i>
<i>Design</i>	<i>Prospective, single arm</i>
<i>Aim</i>	<i>Evaluate balloon assisted coiling with the Scepter balloon and hydrogel coils for the treatment of intracranial aneurysms.</i>
<i>Subjects</i>	<i>Subjects</i>
<i>Primary outcome</i>	<i>Aneurysm recurrence rate at 6 ± 3 month follow up.</i>

Updates:

- Currently enrolling.***
-

ACE Registry – PC 400 System coils

ACE – Study of the Penumbra Coil 400 System to Treat Aneurysm

Study Director	<i>Siu Po Sit, PhD</i>
Design	<i>Prospective, multi-center registry</i>
Aim	<i>To gather post-market data on the PC 400 system</i>
Subjects	<i>2,000 patients with intracranial or peripheral aneurysms. Up to 100 centers.</i>
Primary outcome	<i>• Packing density with the number of coils implanted • Fluoro exposure • Procedural device-related SAEs</i>

Updates:

- Enrollment: 505 patients (70 centers)***
-

VOLCAN Registry

VOLCAN – A Volumetric Coiling in Aneurysm Registry of the Penumbra Coil 400 System in France

<i>PI</i>	<i>Laurent Pierot, MD</i>
<i>Design</i>	<i>Prospective, multi-center</i>
<i>Aim</i>	<i>Registry of patients treated with PC400 system</i>
<i>Subjects</i>	<i>200, 20 centers</i>
<i>Primary outcome</i>	<i>Packing density, fluoro time, immediate SAEs, 1 year Raymond Scale occlusion</i>

Updates:

- Currently recruiting***
-

TARGET Registry

TARGET Intracranial Aneurysm Coiling Registry

National PI	Sam Zaidat, MD MS
Design	Prospective, open label
Aim	Clinical efficacy and safety of Stryker Target 360 and Target 2D coils
Subjects	150
Primary outcome	Packing density

Updates:

- **Enrollment complete**
 - **Preliminary results: Packing density 25.7% +/- 16.3% and was main predictor of complete aneurysm occlusion.**
 - **Second arm to launch**
Will look at Nano technology. Up to 150 additional patients.
-

FEAT Trial – 18 coils vs 10 coils

FEAT -Framing Eighteen Coils in cerebral Aneurysms Trial

National PI	<i>J Mocco, MD, MS</i>
Design	<i>Prospective, randomized</i>
Aim	<i>Compare use of 0.014 – 0.0155 (“18 coils”) vs smaller diameter standard “10 coils” in mid-size aneurysm (6-14 mm) treatment.</i>
Subjects	<i>650 enrolled across 25 sites</i>
Primary outcome	<i>Occlusion rate</i>

Updates:

- Currently enrolled: 150***
 - Sites: 19***
 - Estimated last enrollment: January 2018***
-

NANO – Small aneurysm coiling

NANO Effectiveness and Safety of Small Aneurysm Coiling Trial

<i>National PI</i>	<i>Avery Evans, MD</i>
<i>Design</i>	<i>Prospective, (non-inferiority to large aneurysm coiling)</i>
<i>Aim</i>	<i>Compare safety and efficacy of treating small aneurysms with coils to historically reported rates for larger aneurysms.</i>
<i>Subjects</i>	<i>Ruptured or unruptured, aneurysm < 4 mm</i>
<i>Primary outcome</i>	<i>Composite of technical failure (inability to coil aneurysm) and complication leading to permanent neurologic injury or death. Angiographic recurrence at 12-18 months.</i>

Updates:

- Currently recruiting.***
-

LARGE – Flow diversion versus traditional coiling

LARGE – Aneurysm Randomized Trial: Flow Diversion Versus Traditional Endovascular Coiling Therapy

<i>National PI</i>	<i>Aquilla Turk, DO</i>
<i>Design</i>	<i>Randomized</i>
<i>Aim</i>	<i>Endovascular coiling is non-inferior to flow diversion with respect to a combined safety and efficacy endpoint</i>
<i>Subjects</i>	<ul style="list-style-type: none"><i>• 318</i><i>• Aneurysm \geq 10 mm in paraphthalmic, cavernous, or petrous</i>
<i>Primary outcome</i>	<i>Greater than 90% angiographic occlusion AND stable (or decreased) aneurysm size on cross-sectional imaging at 180 days. AND free of any major neurologic event (change in NIHSS $>$ 4 points)</i>

Updates:

- Recruiting participants***
-

Summary

Ongoing coiling trials and registries aim to evaluate

- ✦ Hydrogel vs bare platinum coils
 - ✦ 18 vs 10 coil systems
 - ✦ Post-market Penumbra 400 system
 - ✦ Nano coils
 - ✦ Flow diversion vs traditional coiling
-